Miacalcic

Calcitonin, the active ingredient in Miacalcic, is a peptide hormone presented as an injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to manage hypercalcemia, osteoporosis, Paget's disease of bone, and bone metastases associated with cancer.

GNH USA supplies Miacalcic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Miacalcic (calcitonin) acts on bone metabolism and calcium regulation, providing therapeutic benefit in several conditions.

- Hypercalcemia: lowers elevated serum calcium levels and alleviates related symptoms. - Osteoporosis: reduces bone resorption, helping to maintain bone density and lower fracture risk. - Paget's disease of bone: normalizes abnormal bone remodeling and decreases bone pain. - Bone metastases associated with cancer: helps control hypercalcemia of malignancy and may reduce skeletal complications.

Calcitonin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset often occurring shortly after injection. - Flushing: transient warmth and redness of the skin. - Headache: mild to moderate pain in the head region. - Injection site reactions: pain, erythema or swelling at the administration site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypocalcemia: markedly low calcium levels that can cause muscle cramps or seizures. - Cardiac arrhythmia: irregular heart rhythm potentially linked to electrolyte disturbances.

When using Miacalcic, several precautionary measures should be observed to ensure safety. - Renal impairment: monitor serum calcium and adjust therapy as needed. - Hypersensitivity: discontinue use if signs of allergic reaction appear. - Pregnancy: prescribe only if potential benefits outweigh potential risks to the fetus. - Concomitant calcium supplements: avoid unless specifically directed by a healthcare professional. - Elderly patients: start with lower doses and monitor for adverse effects closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Calcitonin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Calcium supplements: may diminish the hypocalcemic effect of calcitonin. - Bisphosphonates: combined use can increase the risk of profound hypocalcemia. - Loop diuretics: can exacerbate calcium loss leading to severe hypocalcemia.

Moderate Interactions (Monitor Closely): - Corticosteroids: may reduce calcitonin’s effectiveness on bone resorption. - Thyroid hormones: can interfere with calcium metabolism and require monitoring. - Anticoagulants: when calcitonin is given intravenously, monitor coagulation parameters.